Independent central review of progression in randomized phase II/III oncology trials: Is it needed?


e16558 Background: Time to progression (TTP) or progression free survival (PFS) are increasingly being used as the primary endpoint for phase II/III trials in advanced disease trials in oncology. To minimize the potential bias introduced by subjectivity in radiographic interpretation, an independent review committee (IRC) has often been required in… (More)


  • Presentations referencing similar topics